Citigroup
CUE icon

Citigroup’s Cue Biopharma CUE Stock Holding History

Citigroup’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32 Buy
+1
New +$23 ﹤0.01% 5556
2025
Q4 		– Sell
-4
Closed -$95 – 6136
2025
Q3 		$95 Buy
+4
New +$94 ﹤0.01% 5813
2025
Q1 		– Sell
-1
Closed -$47 – 5664
2024
Q4 		$47 Hold
1
– – ﹤0.01% 5717
2024
Q3 		$33 Sell
1
-167
-99% -$3.62K ﹤0.01% 5581
2024
Q2 		$6.26K Sell
168
-34
-17% -$1.68K ﹤0.01% 5225
2024
Q1 		$11.5K Buy
202
+16
+9% +$1.13K ﹤0.01% 5169
2023
Q4 		$14.7K Buy
186
+185
+18,500% +$13.2K ﹤0.01% 5088
2023
Q3 		$80 Sell
1
-342
-100% -$33.4K ﹤0.01% 5455
2023
Q2 		$37.6K Buy
+343
New +$40.3K ﹤0.01% 4782
2022
Q3 		– Sell
-10
Closed -$1K – 5904
2022
Q2 		$1K Sell
10
-57
-85% -$6.67K ﹤0.01% 6000
2022
Q1 		$10K Sell
67
-2,606
-97% -$553K ﹤0.01% 5523
2021
Q4 		$907K Buy
2,673
+1,733
+184% +$670K ﹤0.01% 3355
2021
Q3 		$411K Sell
940
-1,831
-66% -$639K ﹤0.01% 3746
2021
Q2 		$968K Buy
2,771
+296
+12% +$115K ﹤0.01% 3257
2021
Q1 		$906K Buy
2,475
+2,275
+1,138% +$936K ﹤0.01% 3057
2020
Q4 		$75K Buy
200
+119
+147% +$47.5K ﹤0.01% 5761
2020
Q3 		$36K Sell
81
-1,453
-95% -$837K ﹤0.01% 5793
2020
Q2 		$1.13M Buy
1,534
+1,332
+659% +$965K ﹤0.01% 3437
2020
Q1 		$86K Buy
202
+67
+50% +$32.5K ﹤0.01% 5471
2019
Q4 		$65K Sell
135
-343
-72% -$108K ﹤0.01% 6105
2019
Q3 		$121K Sell
478
-86
-15% -$20.7K ﹤0.01% 5528
2019
Q2 		$152K Buy
564
+4
+0.7% +$995 ﹤0.01% 5504
2019
Q1 		$130K Sell
560
-13
-2% -$2.47K ﹤0.01% 5499
2018
Q4 		$80K Sell
573
-221
-28% -$40.1K ﹤0.01% 5843
2018
Q3 		$216K Buy
794
+77
+11% +$22.2K ﹤0.01% 5169
2018
Q2 		$255K Sell
717
-1,152
-62% -$458K ﹤0.01% 4803
2018
Q1 		$788K Buy
+1,869
New +$852K ﹤0.01% 3487

Other funds holding CUE

BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM

Citigroup's CUE Position: Q2 2026 in Review

Citigroup opened a new position in Cue Biopharma (CUE) in Q2 2026: 1 share worth $32. The stake represents ﹤0.01% of the portfolio and ranks #5556 among its holdings. This is a return to the name: Citigroup previously reported a position in CUE as recently as Q3 2025.

Citigroup first reported a position in CUE in Q1 2018 and has held it in 27 quarters since. The position peaked at $1.13M in Q2 2020. 49 funds tracked by Wall St. Rank hold CUE as of Q2 2026.

  • Citigroup held 1 share of Cue Biopharma worth $32 as of Q2 2026.
  • Cue Biopharma was a new Citigroup position in Q2 2026.
  • Cue Biopharma made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #5556 holding.
  • Citigroup first reported a position in Cue Biopharma in Q1 2018 and has held it in 27 quarters since.
  • Citigroup's Cue Biopharma position peaked at $1.13M in Q2 2020.
  • 49 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.